Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone
Main finding · Severe hypoglycaemiaResult — go to the resultWeighted hazard ratio 1.92 95% CI 1.12–3.30Authors' conclusion
Initiation of amiodarone in patients receiving sulfonylureas was associated with a higher risk of hypoglycemia compared with other antiarrhythmics.
Study context
- Population
- Adults ≥18 years with T2D initiating oral antiarrhythmic therapy while on SU, 2011–2022, South Korean National Health Insurance Service claims; prior first-generation SU, meglitinide, insulin or antiarrhythmic use excluded
- Participants
- 12,730 adults
- Exposure
- Amiodarone vs comparator antiarrhythmics initiated during SU treatment
- Amiodaronen = 5,325
- Comparator antiarrhythmicsn = 7,405reference
- Outcome
- Severe hypoglycaemia: hospital admission or ED visit with primary diagnosis of hypoglycaemia
Methodological detailspropensity score overlap weighting, weighted Cox models
- Propensity score overlap weighting
- Weighted Cox models
Main finding
Severe hypoglycaemia
Weighted hazard ratio
1.92
95% CI 1.12–3.30
Amiodaronevs Comparator antiarrhythmics
weighted HR 1.92 (95% CI 1.12–3.30)
As reported in the abstract
Observational data: associations, not effects.
Further findings
- The increased risk persisted across multiple sensitivity and subgroup analyses
Original publication
Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone. Diabetes Obes Metab. Published 28 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →